Peining Zhu
Zenghui Zhao
Yufei Gao
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1China-Japan Union Hospital of Jilin University, Changchun, China
- 2Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China
- 3Jilin Province Neuro-Oncology Engineering Laboratory, Changchun, China
- 4Jilin Provincial Key Laboratory of Neuro-Oncology, Changchun, China
Currently, few symptomatic and palliative care options are available for patients with Parkinson’s disease (PD). Interdisciplinary research in materials engineering and regenerative medicine has stimulated the development of innovative therapeutic strategy for patients with PD. Hydrogels, which are versatile and accessible to modify, have garnered considerable interests. Hydrogels are a kind of three-dimensional hydrophilic network structure gels that are widely employed in biological materials. Hydrogels are conspicuous in many therapeutic applications, including neuron regeneration, neuroprotection, and diagnosis. This review focuses on the advantageous applications of hydrogel-based biomaterials in diagnosing and treating the patients with PD, including cell culture, disease modeling, carriers for cells, medications and proteins, as well as diagnostic and monitoring biosensors.
GRAPHICAL ABSTRACT
GRAPHICAL ABSTRACT |
1 Introduction
PD is a discernible clinical syndrome characterized by various etiologies and clinical symptoms. Although the pathological changes in PD are complicated, they all entail α-synuclein aggregation (Morris et al., 2024). The current treatment strategies used in clinical practice mainly focus on creating new dopamine (DA) pathways and increasing DA levels. With the development of interdisciplinary studies, the combination of regenerative medicine and biomaterials engineering may provide solutions to the problems faced by current treatment strategies and provide new ideas for new treatment strategies (Pai et al., 2024). Engineering cells and tissue structures has always been employed to enhance the regeneration and/or function restoration after injury, disease or aging in regenerative medicine field. Also, biomaterials coupled with cell replacement technologies are often employed to treat central nervous system (CNS) illnesses by creating a three-dimensional environment for tissue regeneration and repair as well as medication administration. This strategy has been used to circumvent the constraints of dopaminergic neuron repair and regeneration in treating the patients with PD. Hydrogels are a promising therapeutic tool in the field of biomaterials (Harris et al., 2020). In addition to acting as a scaffold for the proliferation of transplanted cells, the hydrogel can also act as a carrier to deliver various active molecules and cells that can treat PD. Additionally, hydrogels have garnered extensive interest in the field of bioelectronic interface materials owing to their resemblance to the extracellular matrix and their versatility in electrical, mechanical, and bioengineering aspects (Han et al., 2018; Jia and Rolandi, 2020; Liang et al., 2021; Lyu et al., 2023; Chen et al., 2024; Li et al., 2024). As a result, hydrogel-based sensors for monitoring and diagnosing PD have become a new research focus in recent years. This review focuses on new hydrogel-based biomaterials for diagnosing and treating PD. Following a summary of hydrogel-based biological materials role in cell transplantation, drug delivery and other therapeutic methods in treating the patients with PD, this review presents the recent researches on biomaterial sensors monitoring and diagnosing PD. Finally, this review identifies the emerging trends, such as new strategies for designing hydrogel-based biomaterials and optimizing existing treatment methods, aiming to provide valuable references for scholars working on the design and development of biomaterials for diagnosing and treating PD, particularly hydrogel-based biomaterials.
2 Parkinson’s disease
PD is a chronic clinical syndrome that ranks second in morbidity only to Alzheimer’s disease as a prevalent neurodegenerative disorder (Feigin et al., 2019; Ben-Shlomo et al., 2024). The incidence and prevalence of PD have increased dramatically over the last 2 decades, for reasons scientists do not entirely understand the pathogenesis (Bloem et al., 2021).
Currently, PD is usually defined as bradykinesia with rigidity, resting tremor, or both. However, PD has multiple subtypes, and the clinical manifestations are diverse, even multi-systematic, including various non-motor symptoms (Chahine et al., 2020; Lancet, 2024). The major pathological characteristics of PD include accelerated loss and death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) induced by complicated interaction mechanisms such as aberrant α-synuclein aggregation, dysfunction of mitochondria, lysosomes or vesicle transport, synaptic transport issues, and neuroinflammation (see Figure 1) (Ben-Shlomo et al., 2024; Lancet, 2024). Due to these complications, there are presently no generally recognized pathologic diagnostic criteria for PD, and efforts to create biomarkers (clinical, imaging, pathological, biochemical, and genetic biomarkers) are continuing (Morris et al., 2024).
Figure 1
Figure 1. The mechanism of Parkinson’s disease.
While medications and surgery may alleviate symptoms of PD to some extent, as the illness exacerbates, they often become less effective and cause varying degrees of adverse effects. The drugs primarily comprise neuroprotective agents that target one or more functionally damaged molecular pathways, as well as others that increase DA concentrations in the brain or activate DA receptor activity (Armstrong and Okun, 2020). Since the pathology of PD mainly involves the loss of dopaminergic neurons, cell transplantation was once considered a viable therapy. However, the low usability, variable functional recovery causing significant movement problems, the undecided optimal cell source, and ethical concerns conspire against cell therapy for PD presently (Parmar et al., 2020).
Regrettably, there is currently no available therapeutic method that may halt or reverse the progression of PD (Dexter and Jenner, 2013). The treatment strategies for patients with PD should now be personalized, and management approaches integrated, i.e., multidisciplinary interventions and cares created by experts with the ultimate objective of assisting patients in meaningful activities and self-management.
3 Hydrogel-based biomaterials in treating the patients with PD
3.1 The advantages of hydrogel-based biomaterials in treating the patients with PD
The use of biomaterials is critical throughout the whole diagnostic and therapeutic process for PD, from diagnosis through medication administration, cell transplantation, in vitro illness simulation, and even disease progression monitoring (Krishnan, 2021). Many biomaterials are critical for growth factor and gene delivery, as well as cell culture and cell transplantation procedures. For instance, some biocompatible materials that promote neuroprotection and regeneration are commonly employed in pharmacological therapy, cell transplantation, and even surgery when treating the patients with PD. These biomaterials have the potential to be employed to carry medications and cells, to generate a three-dimensional physiological environment inside the body, and to serve as implanted electrodes during surgery. The use of biomaterials, as it were, pervades the whole process of treating the patients of PD therapy (Hsieh et al., 2015; Eftekhari et al., 2020; Hejazi et al., 2020; Jarrin et al., 2021).
Hydrogels, an available biomaterial, are recognized as having the best flexibility, convenience and adaptability in meeting many requirements for treating patients with PD. Hydrogel is a porous three-dimensional network structure composed of highly hydrated polymer chains that have been cross-linked by chemical or physical means. The physical cross-linking process is mainly manifested by hydrogen bonding, phase transition, hydrophobic interaction, complex condensation and ionic contact. Chemical crosslinking mechanisms include the Michael addition, the Schiff base reaction, click chemistry, aldehyde crosslinking, photo-crosslinking, and enzyme crosslinking, among others (Fernandez-Serra et al., 2020). The crosslinking method is critical in the formation of the stability and ultimate performance of hydrogels. Electrospinning, biological 3D printing, patterning, freeze-drying, salt immersion, and acellular methods can all be used to design hydrogels for different application (Niemczyk et al., 2018). At present, the polymers formed by hydrogels used in the CNS in clinical practice mainly include three types: self-assembling peptides, synthetic polymers, and natural polymers. Synthetic polymers mainly include poly (ethylene glycol) (PEG), poly (lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and non-biodegradable methacrylate hydrogels. Non-biodegradable methacrylate hydrogels include poly (hydroxypropyl methacrylate) (pHPMA) and poly (2-hydroxyethyl methacrylate) (pHEMA). Natural polymers are mainly divided into two categories: polysaccharide-based polymers (hyaluronic acid (HA), alginate, chitosan, agarose, and methylcellulose) and protein-based polymers [matrigel, gelatin, and collagen (COLL)] (Xie et al., 2024; Zhu et al., 2024).
Designing, researching, and developing biomaterials that can be well applied in brain tissue faces huge challenges due to the complexity and fragility of brain tissue, and the application of hydrogels significantly alleviates these challenges. Hydrogels may be utilized as an implanted scaffold for minimally invasive surgery by injection, allowing for in-situ gelation and precise filling (Rose et al., 2017). With its variable pore size and porosity, excellent biocompatibility, low immunogenicity, low toxicity, adequate biodegradability, and superior electrical and mechanical properties, hydrogels may also simulate extracellular matrix to some degree (Madhusudanan et al., 2020). This enables the development of neuropathy-related environmental models in vitro, as well as the culture and delivery of nerve grafts. Additionally, hydrogels offer an appealing delivery system for unstable medicinal compounds across the blood-brain barrier. Due to their environmental responsiveness and customizable swelling and release characteristics, hydrogels have exhibited promise for developing controlled-release and modified-release dosage carrier agents for CNS disorders (Li and Mooney, 2016). Furthermore, the application of conductive hydrogels prepared from mixed conductive chemicals such as polyaniline, polypyrrole (PPy), and poly (3,4-ethylenedioxythiophene) has significantly stimulated the proliferation, differentiation, development, and extension of neuronal axons (Zhou et al., 2018). Hydrogels may also be used as electrode-related materials for neuromodulation devices, such as flexible and wearable sensors or implants for deep brain stimulation surgery (Kim et al., 2010; Liu et al., 2019). Due of the merits stated above, hydrogels may lead a research path in the biomedical areas of PD-related medication and growth factor administration, bio-sensing, and tissue engineering, among others, see Figure 1.
3.2 Hydrogels in treating the patients with PD
3.2.1 Hydrogels constructing 3D microenvironment to promote cell proliferation and differentiation
The paucity of knowledge about the brain organ precludes the efficacy of therapies for neurodegenerative diseases such as PD. The three-dimensional organoid culture system is now regarded as the most promising technology to recreate the complex function and structure of the human brain (Murphy et al., 2017). Traditional monolayer culture cannot accurately simulate tissue structure, mechanical and biochemical stimuli, and information exchange between cells. However, an organoid culture system can provide a more physiologically relevant in vitro environment, more accurately simulating the interaction of cell-cell, cell-matrix, and cell-surrounding physical environment (mechanical stress and induction, neural cytoskeletal dynamics, and others) (Rammohan et al., 2019; Madhusudanan et al., 2020). Thus, the most genuine neural tissues or organs may be generated in vitro, facilitating the knowledge of the brain’s structure and function.
Along with organoid construction, the use of hydrogels to create a three-dimensional microenvironment that promotes stem cell proliferation and differentiation is critical for treating the patients with PD. Currently, cell transplantation is the primary therapy option for patients with PD who lack compact part of substantia nigra (SNc) dopaminergic neurons (Fan et al., 2020). Induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), and neural stem cells (NSCs) are the most often transplanted cells (Takahashi, 2019). The capacity of these cells to proliferate and differentiate after transplantation into the recipient is critical to the treatment’s effectiveness. Hydrogel-based three-dimensional cell matrix creates an optimal milieu for stem cells to proliferate and differentiate effectively. For example, the development of neural networks and the differentiation of NSCs were significantly promoted after transplantation into hydrogels modified with RGD peptide sequences or cationic moieties (Glotzbach et al., 2020). Additionally, the study showed that iPSCs aggregates could be differentiated into functional dopaminergic neurons after being encapsulated in alginate-Ca2+ hydrogels, and these functional dopaminergic neurons could subsequently be integrated into the host brain by implanting the hydrogels into the host brain (Komatsu et al., 2015). The researchers prepared hydrogels scaffolds to generate cerebral organoids from human pluripotent stem cells (hPSCs) using a medium derived from HA and other particular components. Immunostaining and quantitative reverse transcription-polymerase chain reaction revealed protein and gene expression indicative of forebrain, midbrain, and hindbrain development, and physiological investigations demonstrated that the cells also exhibited neurobehavior as well (Lindborg et al., 2016). This suggests that iPSCs and 3D cell culture are the initial steps toward developing more trustworthy models, like organoids, to aid in research on neurodegenerative disorders. The combination of iPSCs, 3D organoids and bioprinting will also help create novel therapeutics (Bordoni et al., 2018). Neuroinflammation and neurodegeneration are also prominent features of PD, and the activation of microglia and astrocytes plays a significant role in these pathological processes. By culturing microglia and astrocytes in 3D culture media composed of alginate saline hydrogels or COLL hydrogels, important clues for PD research and drug development may be obtained (Watson et al., 2017). As well, by culturing organogenic brain slices from the dorsal striatum and ventral midbrain (VM) in a variety of different biomaterials, the researchers found that dopaminergic fibers grew in culture media containing glialcellline-derivedneurotrophicfactor (GDNF) -loaded COLL hydrogels (Ucar and Humpel, 2019; Ucar et al., 2021). Its ability to progress to both target and non-target brain regions is significantly stimulated. This findings make it possible to preserve or restore connections between the striatum and the SNc in the brain.
Hydrogels may be an advantageous means for regulating cells’ microenvironment and, ultimately, cell assembly and organ development. The cell aggregates generated by these techniques may aid in the development of PD treatments through drug screening, disease modeling, and cell replacement therapy. Although the current research is in its infancy and some issues remain, such as determining which component of the interaction is dominant and determining the critical value of the interaction, the amalgamation of organoid and biomaterial technologies heralds the start of a promising trend in tissue engineering (Wan, 2016).
3.2.2 Delivering drugs and protein molecules
There have been some successful cases of using polymers to construct drug controlled release systems. Among them, the drug controlled release system constructed by hydrogel is a notable case. Hydrogels can significantly increase the ability of drug adsorption, retention, and brain distribution and have unique pharmacokinetic (PK) (Fernandez-Serra et al., 2020). Except for oral, cutaneous, intranasal, and other administration routes, hydrogels can also be administered by in situ injection, thereby efficiently avoiding the obstruction of the blood-brain barrier (Vissers et al., 2019; Del Campo-Montoya et al., 2022; Comini et al., 2024; Comini and Dowd, 2025). Indeed, hydrogels have been widely applied to incorporating medicines, small molecules, extracellular matrix proteins, and even gene vectors to improve and treat chronic illnesses such as PD (Woerly et al., 2008; Singh et al., 2019; Di Stefano and Marinelli, 2021), (see Table 1).
Table 1
Table 1. Hydrogels used for drug and protein delivery in the treatment of PD.
How to effectively deliver DA is the key to treating PD. However, DA can’t penetrate the blood-brain barrier owing to its high hydrogen-bonding potential and hydrophilic properties, posing significant challenges for drug administration to brain tissues (Trapani et al., 2011; Sulzer et al., 2016). Senthilkumar and colleagues (Senthilkumar et al., 2007) utilized self-crosslinked dextran dialdehyde crosslinking gelatin as an injectable DA carrier. The study demonstrated that morphine-induced contralateral rotations were significantly reduced in the 6-hydroxydopamine (6-OHDA) PD animal model after injection of the hydrogel carrier. Another research prepared a DA -loaded nano hydrogel in vitro, whose main component is polyvinylpyrrolidone-polyacrylic acid (PVP/PAAc). This nano hydrogel agent has great potential in brain DA delivery. The findings indicated that the nano- DA administration significantly improved rigor stiffness in the rat model of PD induced by hematoxylin and rotenone, with a significant DA increase in the striatum. Additionally, this method of DA delivery may have disease-modifying effects, as mitochondrial function in brain tissue was significantly enhanced after multiple dosing (Rashed et al., 2015). Ren and colleagues (Ren et al., 2017) developed various injectable and biocompatible hydrogels as local release systems using quaternized chitosan, gelatin, and DA. These hydrogels can administer DA and inflammatory medicines in a slow-release manner. Hence, using hydrogels systems to deliver DA may be a therapeutic strategy for treating patients with PD.
L-DOPA has been the cardinal treatment option for the patients with PD in recent decades (Olanow et al., 2021). However, its low oral bioavailability and low brain absorption need the incorporation with carbidopa to prevent peripheral circulation degradation. As early as 1998, researchers utilized an alcoholic hydrogel containing L-menthol to achieve percutaneous drug administration of L-DOPA to increase brain absorption and enable independent medication usage. L-DOPA and norepinephrine plasma concentrations rose with time. DA levels increased and plateaued thereafter, with no change in adrenaline level (Sudo et al., 1998). Sharma and colleagues prepared chitosan nanoparticles and loaded L-DOPA into them, and then mixed and dispersed the chitosan nanoparticles evenly in a thermoreversible gel made of Pluronic PF127. The intranasal route of administration significantly increases the rate of drug distribution in the brain (Sharma et al., 2014). Additionally, recent research has shown that supramolecular gels composed of glutamine derivatives and benzaldehyde may be employed as delivery vectors for L-DOPA, achieving intranasal administration. The gel has a high degree of biocompatibility with nasal epithelial cells. Animal tests demonstrated that intranasal L-DOPA with a 3H label given through gel was superior to a standard intranasal L-DOPA solution. This is because the gel remained in the nasal cavity longer, resulting in higher blood and brain concentrations (Wang et al., 2021). Combining inorganic particles with hydrogels can give the material additional properties, thereby building a more effective drug delivery system. The optical characteristics, large surface area, biocompatibility, low density, low toxicity, adsorption capacity, and encapsulating ability have garnered considerable interest for silica nanospheres (SiO2). Recently, a study reported that a pH-responsive hydrogel could be synthesized by mixing silica nanospheres with chondroitin sulfate polymer and casein. When this material was used to deliver L-DOPA, L-DOPA could be released continuously by this cell-compatible hydrogel for 87 h (Simão et al., 2020). In addition, in another study, researchers used N, N’-methylenebisacrylamide as a cross-linker and prepared hydrogels with acrylamide (AAm)/methacrylamide (MAAm) and dietary fiber psyllium as raw materials. This hydrogel was found to be able to continuously release neurotransmitter precursors in experiments and can therefore be used to treat the patients with PD (Singh and Chauhan, 2010).
Ropinirole (RP) is one latest DA agonist that works by activating the striatum’s DA receptors to generate DA to treat the patients with PD. RP is effective both as monotherapy and in conjunction with L-DOPA, allowing for a dosage reduction of L-DOPA. However, the oral bioavailability of RP is low, only about 50%, and its short half-life necessitates regular dosing (Azeem et al., 2012). Lipid nanoparticles and their enriched hydrogels formulations are considered to be effective RP delivery systems. Some researchers synthesized nanostructured lipid carriers (RP-NLC) and solid lipid nanoparticles (RP-SLN) and loaded RP into these nanomaterials. The team further synthesized formulations of hydrogels constructed using RP-loaded nanomaterials (RP-SLN-C and RP-NLC-C). The pharmacodynamics (PCD) and PK indicators of these materials were evaluated and optimized. According to the results of PK tests, the bioavailability of RP-loaded nanomaterials and their hydrogel preparations was significantly improved when the administration routes were transdermal and oral. The pharmacodynamics experiments exhibited the recovery of biochemical changes in the rat PD model (Dudhipala and Gorre, 2020). Additionally, many potential therapeutic agents, such as progesterone (Cardia et al., 2019), the chaperone Hsp70 (Tunesi et al., 2019), nicotine (Iresha and Kobayashi, 2021), activins (Li et al., 2016a), and other neuroprotective medicines, are severely restricted by inadequate brain uptake. To a certain degree, the hydrogels delivery system may overcome the restriction of inadequate brain intake. Simultaneously, Chen and colleagues (Chen et al., 2021)established a new PD mouse model. The research team synthesized a thermosensitive hydrogel, the main components of which are poloxamer 188 and poloxamer 407. Due to the temperature-sensitive properties of this drug carrier, they constructed the new animal model by administering paraquat to mice through the nasal cavity. This study provides a new idea for the establishment of PD animal models and makes the operation of establishing PD animal models more convenient.
Many diseases, including PD, have been linked to neurotrophic factors which can regulate nerve cell growth and survival, to influence glial development, and even to function in the systemic system. The delivery of neurotrophic factors to the site of disease and injury presents therapeutic potential in applications, often in conjunction with cell transplantation (Chang and Wang, 2021; Lara-Rodarte et al., 2021). Lampe et al. (2011) used spatially oriented degradable PEG hydrogel as a matrix to encapsulate PLGA particles. This material was used to deliver GDNF and brain-derived neurotrophic factor BDNF to brain regions such as the SNc and striatum. A minimally invasive single penetrating implant design placed the BDNF end into the striatum, and the GDNF end in the SNc. This system demonstrated coordinated medication delivery and decreased immunological and inflammatory responses at the application site. Advances in the manufacturing and processing of hydrogel systems may result in developing novel techniques for the administration of drugs and neurotrophic factors.
3.2.3 Cell transplantation
Dopaminergic neurons in the SNc constitute the majority of the damaged tissue in PD. Although this homogeneous damage makes cell repair treatment an ideal option, the low survival rate of transplanted cells precludes cell repair therapy from extensive clinical application (Sortwell et al., 2000; Schweitzer et al., 2020; Jarrin et al., 2021). In recent years, hydrogels have been widely used in tissue engineering. The main function of hydrogels is to act as scaffolds to encapsulate cells (Oliveira et al., 2018). The injectability, environmental responsiveness, biodegradability, biocompatibility, and ability to simulate the nerve cells environment have garnered considerable interest for hydrogels, particularly in nervous system. Additionally, the porosity of hydrogels promotes cell survival and nerve axon elongation growth (Fernandez-Serra et al., 2020; Pravin and Nivedita, 2020).
When stem cells were cultured using some amyloid hydrogels, they could significantly differentiate toward the neural lineage. The researchers found that this phenomenon was mainly due to the hydrogel’s unique mechanical strength and high-order arrangement (Jacob et al., 2015). By leveraging the self-assembly and physical properties of amyloid protein, Das et al. (2016) prepared a series of hydrogels based on -synuclein (-syn) with the self-recognition sequence motif. In vitro, using this hydrogel to co-culture with mesenchymal stem cells (MSCs), the cultured MSCs can clearly differentiate into the neural lineage. The results showed that after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice were implanted with hydrogels encapsulating MSCs, the survival rate and differentiation rate of MSCs were significantly increased due to the hydrogels. A growing number of studies have demonstrated the merits of conducting hydrogels in bioelectric conductivity, including improving the bioelectrical signals communication between cells, assisting in the restoration of disrupted conductive neural pathways, and preserving the endogenous electrical microenvironment necessary for nerve regeneration. Electrical stimulation of injured nerve tissue alters the regeneration and healing processes significantly (Guo and Ma, 2018; Vijayavenkataraman et al., 2019). Therefore, conductive hydrogels appear critical for both in vitro and in vivo cell culture and implantation. Xue et al. (2019) developed an injectable hydrogel whose main component is Gelatin-PANI. Stereotactic injection of this hydrogel into the SNc region of PD mice can deliver bone marrow stromal cells (BMSCs). The results of this experiment showed that after PD mice received stereotactic injection of hydrogel, the BMSCs in them significantly increased the production of nerve growth factor, nerve fiber fibers and dopaminergic neurons. The behavioral performance of PD mice was also significantly improved. These results suggest that BMSCs can be effectively delivered to the SNc via hydrogels for the treatment of PD. Furthermore, self-assembled peptide hydrogels promote cell survival by providing structural support for functioning, adherent neural networks. Francis et al. (2019) implanted RADA16-I-based self-assembling peptide nanofiber scaffolds (SAPNS) in the striatum of a unilateral 6-OHDA-damage PD mouse model as iPSC-derived human DA Neuronal culture substrates and supports. The results showed that after scaffold implantation, the motor function of the PD mouse model was restored and the long-term survival of cells was significantly promoted. Additionally, modifications to the hydrogels, such as combining them with other materials or adding adhesive peptides, provide physical barriers and adhesion sites for the cells encapsulated in the hydrogels and reduce the mechanical and/or immune pressure experienced by the cells during and after implantation, thereby increasing cell survival (Nakaji-Hirabayashi et al., 2008; 2013; Kang et al., 2014; Adil et al., 2017; Liu et al., 2023) (see Table 2).
Table 2
Table 2. Hydrogels used for cell transplantation in the treatment of PD.
While conventional hydrogels have many benefits, they are a theoretical success. However, it is often discovered in practice that their mechanical qualities are insufficient to structurally safeguard transplanted cells. If the mechanical strength of the hydrogels is increased by the changing hydrogels parameters such as concentration, crosslinking density, and crosslinking distance, the hydrogels’ pore size and transport properties are altered. 3D hydrogels were suggested as a result of this. In other investigations, 3D Ormocomp scaffolds were employed for mechanical enhancement of alginate brine hydrogels, culminating in the formation of 3D mixed scaffolds, which enhanced the mechanical qualities of the composite without altering the pore size of the gel matrix, therefore shielding the encapsulated exogenous cells from the host immune system and enabling them to survive (Kang et al., 2014).
By and large, hydrogels provide an optimal microenvironment for the survival and proliferation of neural lineage cells. Also, given their accessible modification and recombination, the use of hydrogel-coated cells for upgrading the efficacy of stem cell transplantation has enormous promise.
3.2.4 Combined transplantation
Long-term animal and clinical studies on PD have demonstrated that the survival and proliferation of transplanted cells are not always associated with an improvement in clinical symptoms, necessitating guidance and modification to optimize further DA release and DA neuron connectivity (Li et al., 2016b; Kordower et al., 2017; Moriarty et al., 2017). After cell transplantation, hydrogels have been shown to significantly improve the efficacy of PD cell transplantation therapy because they can suppress the host’s immune system and provide the microenvironment required for the growth of transplanted cells. Hydrogels can also be used to carry neurotrophic factors and perform a controlled release. These neurotrophic factors can guide cell behaviors, such as cell survival, growth, scattering, adhesion, proliferation, differentiation, and others (see Table 3). In the future, hydrogels may be designed to transport medicines, gene carriers, and other bioactive ligands for combined transplantation with cells, enhancing the integration of the graft and PD brain, and thus enabling the whole system to more effectively treat the patients with PD.
Table 3
Table 3. Hydrogel used in combined transplantation for PD.
3.3 Hydrogels in PD diagnosis and monitoring - biosensor
Currently, the diagnosis of PD is made mostly on the basis of clinical symptoms and signs, in the absence of accurate imaging and laboratory evaluation. As a result, quantifying early diagnosis and dynamic monitoring of patients with PD is challenging. In recent years, as material engineering science has advanced, researchers have progressively discovered that sensors may be utilized to monitor many indicators of PD patients in order to accomplish early diagnosis and dynamic monitoring. Many ancillary tests are available for diagnosis and monitoring, such as Dopaminergic neuroimaging, Transcranial ultrasound of the SNc, Genetic testing, Copper (serum, 24 h urine), plasma ceruloplasmin, Kayser-Fleischer rings in peripheral cornea, Autonomic function tests, Polysomnography, Olfactory tests, and Tremor analysis (e.g., neurophysiology, accelerometers, wearables) (Guan et al., 2016; Cho et al., 2020; Kim et al., 2020; Lee et al., 2020b).
Wearable sensors are already extensively employed in many medical and non-medical applications. Electrochemical sensors were progressively phased out in favor of flexible optical waveguide sensors, due to their susceptibility to electromagnetic interference and associated electrical safety issues. Apart from optical transmission, waveguides may be built and functionalized for high-sensitivity sensing by altering light intensity, phase, wavelength, or polarization. These devices can achieve wearable/implantable physiological monitoring (e.g., heart rate, body temperature), mechanical monitoring (e.g., pressure, strain, torsion), and biochemical monitoring of the body (e.g., glucose, sweat, oxygen saturation) (Nag et al., 2017; Guo et al., 2019). This sensor is a simple, non-invasive, and stress-free method of monitoring and diagnosing PD patients. Due to their superior optical and mechanical capabilities, hydrogels have become an essential biological material for use in these sensors (Guimarães et al., 2021). DA is a central monoamine neurotransmitter. Blocked DA transmission is strongly associated with the onset and development of PD. Zhou et al. (2020) developed a soft and biocompatible optical DA sensor based on doped hydrogels optical fiber (HOF) with upconversion nanoparticles (UCNPs). The detection of DA molecules is accomplished via the luminous energy transfer between UCNPs and the oxidation products of DA, while photoconductive HOF could collect UCNPs during excitation and emission. Due to its high linearity, selectivity, and sensitivity, the polyethylene glycol diacrylate (PEGDA) hydrogel-based sensor UCNPS-HOF can reliably detect DA in the 0–200 M range (LOD at 83.6 nM).
This hydrogel-based optical sensor may be utilized as a bedside sensor probe for quantitative and in-situ monitoring of DA. It has clinical use in the study and diagnosis of DA-related disorders. Additionally, several studies concentrate on the dynamic monitoring of patients with PD after therapy. Transient fingertip perspiration was collected using a highly permeable hydrogel in a study of customized therapeutic medication monitoring in the patient with PD after oral L-DOPA administration. The hydrogels transported perspiration to a biocatalytic tyrosinase-modified electrode, which finally transformed into a fingertip L-DOPA biosensor capable of monitoring the dynamic features of the patient with PD while they are on L-DOPA (Moon et al., 2021). Similar investigations include combinatorial biophysical cue sensor developed by Jong MinLee et al. utilizing conductive PEG hydrogels. The sensor and topographical/geometrical cues were fused together via electrical stimulation, and could be used to study the proliferation and differentiation of NSCs, as well as a monitoring and intervention tool for stem cell transplantation treatment for the patients with PD (Lee et al., 2020a).
Kim et al. (2021) demonstrated the use of a highly stretchy and self-healing hydrogels conductor (CCDHG) composed of catechol, chitosan, and diatom as stretchable triboelectric nanogenerators (TENG). TENG is used to harvest energy from human motion and apply a self-powered tremor sensor to the skin for long-term monitoring of the health status of PD patients. Using machine learning algorithms, m-shaped Kapton film and a specifically developed ccDHG-Teng self-powered tremor sensor were utilized to detect and track low-frequency vibration movements in PD patients. This research introduces a novel method for constructing stretchy TENGs utilizing conductive hydrogels. These materials can be utilized in many applications, including stretchable power supply, wearable electronics, and artificial intelligence-enabled health monitoring systems.
Additionally, Bin Yao and colleagues developed a highly sensitive wireless rehabilitation training ball with a piezoresistive sensor array for patients with PD. The piezoresistive material used in the rehabilitation training ball is a conductive hydrogels with a low permeability threshold, generated by conductive PPy nanofibers (NFs) grown from a polydopamine (PDA) template. Conductive hydrogels are capable of discriminating between 15.40 Pa slight pressures. The use of very sensitive piezoresistive sensors enables the monitoring of hand grip strength, which is poorly regulated in patients with PD. The rehabilitation training ball is equipped on the surface with a sensor array and a wireless chip assembly for internal communication, which enables real-time pressure monitoring (Yao et al., 2022). The use of hydrogels on different sensors, as it were, has aided in the research and development of monitoring equipment for PD patients, delivering good news for their treatment and rehabilitation, and perhaps facilitating the early quantitative diagnosis of PD (see Table 4).
Table 4
Table 4. Application of hydrogel-based biosensors in PD.
4 Conclusion and outlook
Through long-term and effective control of the cell microenvironment, hydrogels can effectively manage the process of cell assembly and organ development. Problems faced in drug screening, the use of cell replacement therapy to treat PD patients, and the development of new PD models may be solved by the introduction of hydrogels and related cell aggregates. In addition to the advantage of being able to respond quickly and effectively to stimuli generated by various environmental conditions, hydrogels also have the obvious advantage of having multiple forms (multi-channels, nanohydrogels, microbeads, etc.). At the same time, hydrogels can be effectively combined with nanoparticles to achieve better results. At present, in the treatment of PD proteins, drugs, cells, genes, etc., there is a lot of data proving that hydrogels can be used as an excellent delivery carrier. Hydrogels may serve as an ideal bioelectronic interface medium, especially in contact with the human body, by combining their electrical conductivity with the bioelectric conductivity of nerve tissue. Thus, hydrogels serve as the interface material for electrical stimulation and recording brain activity, enabling the development of sensors and neural prostheses to monitor and treat PD-related movement deficits (see Figure 2).
Figure 2
Figure 2. Hydrogels applied to the modeling and treatment of neurological diseases. (A) Hydrogels applied to drug and soluble factor delivery (B) Hydrogels as delivery carrier for transplanted cells (C, D) Hydrogels is as scaffolds to promote the nerve cells growth (E, F) Hydrogels aiding in the in vitro modeling of the nervous system and CNS organoid.
Although significant progress has been made in the research of hydrogels in recent years, hydrogels still have certain challenges in the diagnosis, treatment and detection of PD. For example, for hydrogels that will be implanted in tissues for a long time, how to accurately simulate the physical properties and mechanical properties of natural tissues is an urgent problem to be solved. These properties include the long-term stability, bioelectric conductivity and strength of the material. At the same time, after the hydrogels are implanted in tissues and organs for a long time, it may age over time, and its performance will decline, which may even make it difficult for the implant to maintain its original form. These problems may weaken the ability of hydrogels to support the attachment, proliferation and migration of co-transplanted cells. These abilities are essential for effective tissue repair and functional recovery, so how to balance the biological function and physical properties of hydrogels may be one of the focuses of future hydrogels research.
Another challenge faced by the application of hydrogels in the treatment of PD is how hydrogels can accurately simulate the signals of extracellular matrix. When stem cells are co-transplanted to treat PD, the proliferation, differentiation and integration of stem cells in tissues are important ways for it to play a role. How to accurately simulate the signals of extracellular matrix to accurately control the behavior of stem cells may also be the future research direction of hydrogels for the treatment of PD.
In addition, with the further development of the field of materials science, bioink and 3D printing technology are gradually used, which makes the design of hydrogels tend to be customized separately for each patient. At the same time, these technologies can form a more complex hydrogels structure and adapt to the intricate environment in the brain.
To summarize, the use of hydrogels in diagnosing and treating the patients with PD is an interesting and fast-evolving area.
Author contributions
PZ: Conceptualization, Investigation, Visualization, Writing–original draft, Writing–review and editing. ZZ: Investigation, Writing–original draft. YG: Funding acquisition, Project administration, Supervision, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by National Development and Reform Commission (Grant No. 2022C043-1). This work was also supported by Jilin Province Neuro-oncology Engineering Laboratory, Changchun, China and Jilin Provincial Key Laboratory of Neuro-oncology, Changchun, China.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Adil, M. M., Rao, A. T., Ramadoss, G. N., Chernavsky, N. E., Kulkarni, R. U., Miller, E. W., et al. (2018). Dopaminergic neurons transplanted using cell-instructive biomaterials alleviate parkinsonism in rodents. Adv. Funct. Mater. 28 (41), 1804144. doi:10.1002/adfm.201804144
Adil, M. M., Vazin, T., Ananthanarayanan, B., Rodrigues, G. M. C., Rao, A. T., Kulkarni, R. U., et al. (2017). Engineered hydrogels increase the post-transplantation survival of encapsulated hESC-derived midbrain dopaminergic neurons. Biomaterials 136, 1–11. doi:10.1016/j.biomaterials.2017.05.008
Armstrong, M. J., and Okun, M. S. (2020). Choosing a Parkinson disease treatment. Jama 323 (14), 1420. doi:10.1001/jama.2020.1224
Azeem, A., Talegaonkar, S., Negi, L. M., Ahmad, F. J., Khar, R. K., and Iqbal, Z. (2012). Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int. J. Pharm. 422 (1), 436–444. doi:10.1016/j.ijpharm.2011.10.039
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., and Tanner, C. (2024). The epidemiology of Parkinson's disease. Lancet 403 (10423), 283–292. doi:10.1016/S0140-6736(23)01419-8
Bloem, B. R., Okun, M. S., and Klein, C. (2021). Parkinson's disease. Lancet 397 (10291), 2284–2303. doi:10.1016/S0140-6736(21)00218-X
Bordoni, M., Rey, F., Fantini, V., Pansarasa, O., Di Giulio, A. M., Carelli, S., et al. (2018). From neuronal differentiation of iPSCs to 3D neuro-organoids: modelling and therapy of neurodegenerative diseases. Int. J. Mol. Sci. 19 (12), 3972. doi:10.3390/ijms19123972
Carballo-Molina, O. A., Sánchez-Navarro, A., López-Ornelas, A., Lara-Rodarte, R., Salazar, P., Campos-Romo, A., et al. (2016). Semaphorin 3C released from a biocompatible hydrogel guides and promotes axonal growth of rodent and human dopaminergic neurons. Tissue Eng. Part A 22 (11-12), 850–861. doi:10.1089/ten.tea.2016.0008
Cardia, M. C., Carta, A. R., Caboni, P., Maccioni, A. M., Erbi, S., Boi, L., et al. (2019). Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders. Pharmaceutics 11 (12), 657. doi:10.3390/pharmaceutics11120657
Chahine, L. M., Beach, T. G., Brumm, M. C., Adler, C. H., Coffey, C. S., Mosovsky, S., et al. (2020). In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology 95 (9), e1267–e1284. doi:10.1212/WNL.0000000000010404
Chang, E., and Wang, J. (2021). Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease. Brain Behav. 11, e2251. doi:10.1002/brb3.2251
Chen, R.-S., Gao, M., Chu, D., Cheng, W., and Lu, Y. (2024). Self-powered hydrogel wearable bioelectronics. Nano Energy 128, 109960. doi:10.1016/j.nanoen.2024.109960
Chen, Y.-B., Wang, Y.-Q., Wu, J.-R., and Cui, Y.-L. (2021). A novel idea for establishing Parkinson's disease mouse model by intranasal administration of paraquat. Neurological Res. 43 (4), 267–277. doi:10.1080/01616412.2020.1847542
Cho, Y.-W., Park, J.-H., Lee, K.-H., Lee, T., Luo, Z., and Kim, T.-H. (2020). Recent advances in nanomaterial-modified electrical platforms for the detection of dopamine in living cells. Nano Converg. 7 (1), 40. doi:10.1186/s40580-020-00250-7
Comini, G., and Dowd, E. (2025). The loaded matrix: neurotrophin-enriched hydrogels for stem cell brain repair in Parkinson's disease. Neural Regen. Res. 20 (8), 2315–2316. doi:10.4103/nrr.Nrr-d-24-00586
Comini, G., Kelly, R., Jarrin, S., Patton, T., Narasimhan, K., Pandit, A., et al. (2024). Survival and maturation of human induced pluripotent stem cell-derived dopaminergic progenitors in the parkinsonian rat brain is enhanced by transplantation in a neurotrophin-enriched hydrogel. J. Neural Eng. 21 (2), 024002. doi:10.1088/1741-2552/ad33b2
Das, S., Zhou, K., Ghosh, D., Jha, N. N., Singh, P. K., Jacob, R. S., et al. (2016). Implantable amyloid hydrogels for promoting stem cell differentiation to neurons. NPG Asia Mater. 8 (9), e304. doi:10.1038/am.2016.116
Del Campo-Montoya, R., Luquin, M. R., Puerta, E., Garbayo, E., and Blanco-Prieto, M. J. (2022). Hydrogels for brain repair: application to Parkinson's disease. Expert Opin. Drug Deliv. 19 (11), 1521–1537. doi:10.1080/17425247.2022.2136161
Dexter, D. T., and Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132–144. doi:10.1016/j.freeradbiomed.2013.01.018
Di Stefano, A., and Marinelli, L. (2021). Advances in Parkinson's disease drugs. Biomolecules 11 (11), 1640. doi:10.3390/biom11111640
Dudhipala, N., and Gorre, T. (2020). Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for Parkinson's disease: in vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics 12 (5), 448. doi:10.3390/pharmaceutics12050448
Eftekhari, B. S., Eskandari, M., Janmey, P. A., Samadikuchaksaraei, A., and Gholipourmalekabadi, M. (2020). Surface topography and electrical signaling: single and synergistic effects on neural differentiation of stem cells. Adv. Funct. Mater. 30 (25). doi:10.1002/adfm.201907792
Fan, Y., Winanto, , and Ng, S.-Y. (2020). Replacing what’s lost: a new era of stem cell therapy for Parkinson’s disease. Transl. Neurodegener. 9 (1), 2. doi:10.1186/s40035-019-0180-x
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., et al. (2019). Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18 (5), 459–480. doi:10.1016/s1474-4422(18)30499-x
Fernandez-Serra, R., Gallego, R., Lozano, P., and González-Nieto, D. (2020). Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering. Neural Regen. Res. 15 (5), 783–789. doi:10.4103/1673-5374.268891
Francis, N. L., Zhao, N., Calvelli, H. R., Saini, A., Gifford, J. J., Wagner, G. C., et al. (2019). Peptide-based scaffolds for the culture and transplantation of human dopaminergic neurons. Tissue Eng. Part A 26 (3-4), 193–205. doi:10.1089/ten.tea.2019.0094
Glotzbach, K., Stamm, N., Weberskirch, R., and Faissner, A. (2020). Hydrogels derivatized with cationic moieties or functional peptides as efficient supports for neural stem cells. Stem Cells 14 (475), 475. doi:10.3389/fnins.2020.00475
Guan, L., Nilghaz, A., Su, B., Jiang, L., Cheng, W., and Shen, W. (2016). Stretchable-fiber-confined wetting conductive liquids as wearable human health monitors. Adv. Funct. Mater. 26 (25), 4511–4517. doi:10.1002/adfm.201600443
Guimarães, C. F., Ahmed, R., Marques, A. P., Reis, R. L., and Demirci, U. (2021). Engineering hydrogel-based biomedical photonics: design, fabrication, and applications. Adv. Mater. 33 (23), 2006582. doi:10.1002/adma.202006582
Guo, B., and Ma, P. X. (2018). Conducting polymers for tissue engineering. Biomacromolecules 19 (6), 1764–1782. doi:10.1021/acs.biomac.8b00276
Guo, J., Yang, C., Dai, Q., and Kong, L. (2019). Soft and stretchable polymeric optical waveguide-based sensors for wearable and biomedical applications. Sensors 19 (17), 3771. doi:10.3390/s19173771
Han, L., Yan, L., Wang, M., Wang, K., Fang, L., Zhou, J., et al. (2018). Transparent, adhesive, and conductive hydrogel for soft bioelectronics based on light-transmitting polydopamine-doped polypyrrole nanofibrils. Chem. Mater. 30 (16), 5561–5572. doi:10.1021/acs.chemmater.8b01446
Harris, J. P., Burrell, J. C., Struzyna, L. A., Chen, H. I., Serruya, M. D., Wolf, J. A., et al. (2020). Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease. npj Parkinson's Dis. 6 (1), 4. doi:10.1038/s41531-019-0105-5
Hejazi, M. A., Tong, W., Stacey, A., Soto-Breceda, A., Ibbotson, M. R., Yunzab, M., et al. (2020). Hybrid diamond/carbon fiber microelectrodes enable multimodal electrical/chemical neural interfacing. Biomaterials 230, 119648. doi:10.1016/j.biomaterials.2019.119648
Hsieh, F.-Y., Tseng, T.-C., and Hsu, S.-h. (2015). Self-healing hydrogel for tissue repair in the central nervous system. Neural Regen. Res. 10 (12), 1922–1923. doi:10.4103/1673-5374.169624
Hunt, C. P. J., Penna, V., Gantner, C. W., Moriarty, N., Wang, Y., Franks, S., et al. (2021). Tissue programmed hydrogels functionalized with GDNF improve human neural grafts in Parkinson's disease. Adv. Funct. Mater. 31 (47), 2105301. doi:10.1002/adfm.202105301
Iresha, H., and Kobayashi, T. (2021). Ultrasound-triggered nicotine release from nicotine-loaded cellulose hydrogel. Ultrason. Sonochemistry 78, 105710. doi:10.1016/j.ultsonch.2021.105710
Jacob, R. S., Ghosh, D., Singh, P. K., Basu, S. K., Jha, N. N., Das, S., et al. (2015). Self healing hydrogels composed of amyloid nano fibrils for cell culture and stem cell differentiation. Biomaterials 54, 97–105. doi:10.1016/j.biomaterials.2015.03.002
Jarrin, S., Cabré, S., and Dowd, E. (2021). The potential of biomaterials for central nervous system cellular repair. Neurochem. Int. 144, 104971. doi:10.1016/j.neuint.2021.104971
Jia, M., and Rolandi, M. (2020). Soft and ion-conducting materials in bioelectronics: from conducting polymers to hydrogels. Adv. Healthc. Mater. 9 (5), e1901372. doi:10.1002/adhm.201901372
Kang, K. S., Lee, S.-I., Hong, J. M., Lee, J. W., Cho, H. Y., Son, J. H., et al. (2014). Hybrid scaffold composed of hydrogel/3D-framework and its application as a dopamine delivery system. J. Control. Release 175, 10–16. doi:10.1016/j.jconrel.2013.12.002
Kim, D.-H., Wiler, J. A., Anderson, D. J., Kipke, D. R., and Martin, D. C. (2010). Conducting polymers on hydrogel-coated neural electrode provide sensitive neural recordings in auditory cortex. Acta Biomater. 6 (1), 57–62. doi:10.1016/j.actbio.2009.07.034
Kim, J.-N., Lee, J., Lee, H., and Oh, I.-K. (2021). Stretchable and self-healable catechol-chitosan-diatom hydrogel for triboelectric generator and self-powered tremor sensor targeting at Parkinson disease. Nano Energy 82, 105705. doi:10.1016/j.nanoen.2020.105705
Kim, S., Cho, M., and Lee, Y. (2020). Point-of-Care platform for early diagnosis of Parkinson's disease. Acs Appl. Bio Mater. 3 (12), 8997–9001. doi:10.1021/acsabm.0c01242
Komatsu, M., Konagaya, S., Egawa, E. Y., and Iwata, H. (2015). Maturation of human iPS cell-derived dopamine neuron precursors in alginate–Ca2+ hydrogel. Biochimica Biophysica Acta (BBA) - General Subj. 1850 (9), 1669–1675. doi:10.1016/j.bbagen.2015.04.011
Kordower, J. H., Goetz, C. G., Chu, Y., Halliday, G. M., Nicholson, D. A., Musial, T. F., et al. (2017). Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann. Neurol. 81 (1), 46–57. doi:10.1002/ana.24820
Krishnan, U. M. (2021). Biomaterials in the treatment of Parkinson's disease. Neurochem. Int. 145, 105003. doi:10.1016/j.neuint.2021.105003
Lampe, K. J., Kern, D. S., Mahoney, M. J., and Bjugstad, K. B. (2011). The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response. J. Biomed. Mater. Res. A 96A (3), 595–607. doi:10.1002/jbm.a.33011
Lancet, T. (2024). What next in Parkinson's disease? Lancet 403 (10423), 219. doi:10.1016/s0140-6736(24)00094-1
Lara-Rodarte, R., Cortés, D., Soriano, K., Carmona, F., Rocha, L., Estudillo, E., et al. (2021). Mouse embryonic stem cells expressing GDNF show enhanced dopaminergic differentiation and promote behavioral recovery after grafting in parkinsonian rats. Front. Cell Dev. Biol. 9 (1480), 661656. doi:10.3389/fcell.2021.661656
Lee, J. M., Kang, W. S., Lee, K. G., Cho, H.-Y., Conley, B., Ahrberg, C. D., et al. (2020a). Combinatorial biophysical cue sensor array for controlling neural stem cell fate. Biosens. Bioelectron. 156, 112125. doi:10.1016/j.bios.2020.112125
Lee, M.-H., Liu, K.-T., Thomas, J. L., Su, Z.-L., O'Hare, D., van Wuellen, T., et al. (2020b). Peptide-imprinted poly(hydroxymethyl 3,4-ethylenedioxythiophene) nanotubes for detection of α synuclein in human brain organoids. Acs Appl. Nano Mater. 3 (8), 8027–8036. doi:10.1021/acsanm.0c01476
Li, J., Darabi, M., Gu, J., Shi, J., Xue, J., Huang, L., et al. (2016a). A drug delivery hydrogel system based on activin B for Parkinson's disease. Biomaterials 102, 72–86. doi:10.1016/j.biomaterials.2016.06.016
Li, J., and Mooney, D. J. (2016). Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 1 (12), 16071. doi:10.1038/natrevmats.2016.71
Li, W., Englund, E., Widner, H., Mattsson, B., van Westen, D., Lätt, J., et al. (2016b). Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl. Acad. Sci. U. S. A. 113 (23), 6544–6549. doi:10.1073/pnas.1605245113
Li, Z., Lu, J., Ji, T., Xue, Y., Zhao, L., Zhao, K., et al. (2024). Self-healing hydrogel bioelectronics. Adv. Mater 36 (21), e2306350. doi:10.1002/adma.202306350
Liang, Y., Offenhausser, A., Ingebrandt, S., and Mayer, D. (2021). PEDOT:PSS-Based bioelectronic devices for recording and modulation of electrophysiological and biochemical cell signals. Adv. Healthc. Mater. 10 (11), e2100061. doi:10.1002/adhm.202100061
Lindborg, B. A., Brekke, J. H., Vegoe, A. L., Ulrich, C. B., Haider, K. T., Subramaniam, S., et al. (2016). Rapid induction of cerebral organoids from human induced pluripotent stem cells using a chemically defined hydrogel and defined cell culture medium. Stem Cells Transl. Med. 5 (7), 970–979. doi:10.5966/sctm.2015-0305
Liu, T., Zhang, Q., Li, H., Cui, X., Qi, Z., and Yang, X. (2023). An injectable, self-healing, electroconductive hydrogel loaded with neural stem cells and donepezil for enhancing local therapy effect of spinal cord injury. J. Biol. Eng. 17 (1), 48. doi:10.1186/s13036-023-00368-2
Liu, Y., Liu, J., Chen, S., Lei, T., Kim, Y., Niu, S., et al. (2019). Soft and elastic hydrogel-based microelectronics for localized low-voltage neuromodulation. Nat. Biomed. Eng. 3 (1), 58–68. doi:10.1038/s41551-018-0335-6
Lyu, X., Hu, Y., Shi, S., Wang, S., Li, H., Wang, Y., et al. (2023). Hydrogel bioelectronics for health monitoring. Biosens. (Basel) 13 (8), 815. doi:10.3390/bios13080815
Madhusudanan, P., Raju, G., and Shankarappa, S. (2020). Hydrogel systems and their role in neural tissue engineering. J. R. Soc. Interface 17 (162), 20190505. doi:10.1098/rsif.2019.0505
Moon, J.-M., Teymourian, H., De la Paz, E., Sempionatto, J. R., Mahato, K., Sonsa-ard, T., et al. (2021). Non-invasive sweat-based tracking of L-dopa pharmacokinetic profiles following an oral tablet administration. Angew. Chem. Int. Ed. 60 (35), 19074–19078. doi:10.1002/anie.202106674
Moriarty, N., Cabré, S., Alamilla, V., Pandit, A., and Dowd, E. (2019). Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemi-Parkinsonian rats. Eur. J. Neurosci. 49 (4), 487–496. doi:10.1111/ejn.14090
Moriarty, N., Pandit, A., and Dowd, E. (2017). Encapsulation of primary dopaminergic neurons in a GDNF-loaded collagen hydrogel increases their survival, re-innervation and function after intra-striatal transplantation. Sci. Rep. 7, 16033. doi:10.1038/s41598-017-15970-w
Morris, H. R., Spillantini, M. G., Sue, C. M., and Williams-Gray, C. H. (2024). The pathogenesis of Parkinson's disease. Lancet 403 (10423), 293–304. doi:10.1016/s0140-6736(23)01478-2
Murphy, A. R., Laslett, A., O'Brien, C. M., and Cameron, N. R. (2017). Scaffolds for 3D in vitro culture of neural lineage cells. Acta Biomater. 54, 1–20. doi:10.1016/j.actbio.2017.02.046
Nag, A., Mukhopadhyay, S. C., and Kosel, J. (2017). Wearable flexible sensors: a review. IEEE Sensors J. 17 (13), 3949–3960. doi:10.1109/JSEN.2017.2705700
Nakaji-Hirabayashi, T., Kato, K., and Iwata, H. (2008). Self-assembling chimeric protein for the construction of biodegradable hydrogels capable of interaction with integrins expressed on neural stem/progenitor cells. Biomacromolecules 9 (5), 1411–1416. doi:10.1021/bm701423d
Nakaji-Hirabayashi, T., Kato, K., and Iwata, H. (2009). Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier. Biomaterials 30 (27), 4581–4589. doi:10.1016/j.biomaterials.2009.05.009
Nakaji-Hirabayashi, T., Kato, K., and Iwata, H. (2013). In vivo study on the survival of neural stem cells transplanted into the rat brain with a collagen hydrogel that incorporates laminin-derived polypeptides. Bioconjugate Chem. 24 (11), 1798–1804. doi:10.1021/bc400005m
Niemczyk, B., Sajkiewicz, P., and Kolbuk, D. (2018). Injectable hydrogels as novel materials for central nervous system regeneration. J. Neural Eng. 15 (5), 051002. doi:10.1088/1741-2552/aacbab
Olanow, C. W., Poewe, W., Rascol, O., and Stocchi, F. (2021). On-demand therapy for OFF episodes in Parkinson's disease. Mov. Disord. 36 (10), 2244–2253. doi:10.1002/mds.28726
Oliveira, E. P., Silva-Correia, J., Reis, R. L., and Oliveira, J. M. (2018). Biomaterials developments for brain tissue engineering. Adv. Exp. Med. Biol. 1078, 323–346. doi:10.1007/978-981-13-0950-2_17
Pai, V., Singh, B. N., and Singh, A. K. (2024). Insights into advances and applications of biomaterials for nerve tissue injuries and neurodegenerative disorders. Macromol. Biosci. 24 (12), e2400150. doi:10.1002/mabi.202400150
Parmar, M., Grealish, S., and Henchcliffe, C. (2020). The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21 (2), 103–115. doi:10.1038/s41583-019-0257-7
Pravin, S., and Nivedita, G. (2020). Current trend and pro-survival approaches for augmenting stem cell viability. Curr. Pharm. Biotechnol. 21 (12), 1154–1164. doi:10.2174/1389201021666200416130253
Rammohan, A. R., Rangamani, P., and Stolarska, M. (2019). A minimal mechanochemical model for growth cone dynamics. Biophysical J. 116 (3), 124a. doi:10.1016/j.bpj.2018.11.690
Rashed, E. R., Abd El-Rehim, H. A., and El-Ghazaly, M. A. (2015). Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity. J. Biomed. Mater Res. A103(5), 1713–1720. doi:10.1002/jbm.a.35312
Ren, Y., Zhao, X., Liang, X., Ma, P. X., and Guo, B. (2017). Injectable hydrogel based on quaternized chitosan, gelatin and dopamine as localized drug delivery system to treat Parkinson’s disease. Int. J. Biol. Macromol. 105, 1079–1087. doi:10.1016/j.ijbiomac.2017.07.130
Rose, J. C., Cámara-Torres, M., Rahimi, K., Köhler, J., Möller, M., and De Laporte, L. (2017). Nerve cells decide to orient inside an injectable hydrogel with minimal structural guidance. Nano Lett. 17 (6), 3782–3791. doi:10.1021/acs.nanolett.7b01123
Schweitzer, J. S., Song, B., Herrington, T. M., Park, T.-Y., Lee, N., Ko, S., et al. (2020). Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N. Engl. J. Med. 382 (20), 1926–1932. doi:10.1056/NEJMoa1915872
Senthilkumar, K. S., Saravanan, K. S., Chandra, G., Sindhu, K. M., Jayakrishnan, A., and Mohanakumar, K. P. (2007). Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behav. Brain Res. 184 (1), 11–18. doi:10.1016/j.bbr.2007.06.025
Sharma, S., Lohan, S., and Murthy, R. S. R. (2014). Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev. Industrial Pharm. 40 (7), 869–878. doi:10.3109/03639045.2013.789051
Simão, A. R., Fragal, V. H., Lima, A. M. d.O., Pellá, M. C. G., Garcia, F. P., Nakamura, C. V., et al. (2020). pH-responsive hybrid hydrogels: chondroitin sulfate/casein trapped silica nanospheres for controlled drug release. Int. J. Biol. Macromol. 148, 302–315. doi:10.1016/j.ijbiomac.2020.01.093
Singh, A. P., Biswas, A., Shukla, A., and Maiti, P. (2019). Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target Ther. 4, 33. doi:10.1038/s41392-019-0068-3
Singh, B., and Chauhan, N. (2010). Release dynamics of tyrosine from dietary fiber psyllium based hydrogels for use in Parkinson’s disease. Food Res. Int. 43 (4), 1065–1072. doi:10.1016/j.foodres.2010.01.015
Sortwell, C. E., Pitzer, M. R., and Collier, T. J. (2000). Time course of apoptotic cell death within mesencephalic cell suspension grafts: implications for improving grafted dopamine neuron survival. Exp. Neurol. 165 (2), 268–277. doi:10.1006/exnr.2000.7476
Sudo, J.-i., Iwase, H., Terui, J., Kakuno, K., Momoko, S., Takayama, K., et al. (1998). Transdermal absorption of l-dopa from hydrogel in rats. Eur. J. Pharm. Sci. 7 (1), 67–71. doi:10.1016/S0928-0987(98)00007-4
Sulzer, D., Cragg, S. J., and Rice, M. E. (2016). Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia 6 (3), 123–148. doi:10.1016/j.baga.2016.02.001
Takahashi, J. (2019). Preparing for first human trial of induced pluripotent stem cell-derived cells for Parkinson's disease: an interview with Jun Takahashi. Regen. Med. 14 (2), 93–95. doi:10.2217/rme-2018-0158
Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., et al. (2011). Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm. 419 (1), 296–307. doi:10.1016/j.ijpharm.2011.07.036
Tunesi, M., Raimondi, I., Russo, T., Colombo, L., Micotti, E., Brandi, E., et al. (2019). Hydrogel-based delivery of Tat-fused protein Hsp70 protects dopaminergic cells in vitro and in a mouse model of Parkinson’s disease. NPG Asia Mater. 11 (1), 28. doi:10.1038/s41427-019-0128-8
Ucar, B., and Humpel, C. (2019). Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson’s disease models. Brain Res. Bull. 149, 86–95. doi:10.1016/j.brainresbull.2019.04.012
Ucar, B., Kajtez, J., Foidl, B. M., Eigel, D., Werner, C., Long, K. R., et al. (2021). Biomaterial based strategies to reconstruct the nigrostriatal pathway in organotypic slice co-cultures. Acta Biomater. 121, 250–262. doi:10.1016/j.actbio.2020.11.035
Vijayavenkataraman, S., Vialli, N., Fuh, J. Y. H., and Lu, W. F. (2019). Conductive collagen/polypyrrole-b-polycaprolactone hydrogel for bioprinting of neural tissue constructs. Int. J. Bioprint 5 (2.1), 229. doi:10.18063/ijb.v5i2.1.229
Vissers, C., Ming, G.-l., and Song, H. (2019). Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv. Drug Deliv. Rev. 148, 239–251. doi:10.1016/j.addr.2019.02.007
Wan, A. C. A. (2016). Recapitulating cell–cell interactions for organoid construction – are biomaterials dispensable? Trends Biotechnol. 34 (9), 711–721. doi:10.1016/j.tibtech.2016.02.015
Wang, J.T.-W., Rodrigo, A. C., Patterson, A. K., Hawkins, K., Aly, M. M. S., Sun, J., et al. (2021). Enhanced delivery of neuroactive drugs via nasal delivery with a self-healing supramolecular gel. Adv. Sci. Weinheim, Baden-Wurttemberg, Ger. 8 (14), e2101058. doi:10.1002/advs.202101058
Wang, T.-Y., Bruggeman, K. F., Kauhausen, J. A., Rodriguez, A. L., Nisbet, D. R., and Parish, C. L. (2016). Functionalized composite scaffolds improve the engraftment of transplanted dopaminergic progenitors in a mouse model of Parkinson's disease. Biomaterials 74, 89–98. doi:10.1016/j.biomaterials.2015.09.039
Watson, P. M. D., Kavanagh, E., Allenby, G., and Vassey, M. (2017). Bioengineered 3D glial cell culture systems and applications for neurodegeneration and neuroinflammation. SLAS Discov. Adv. Sci. Drug Discov. 22 (5), 583–601. doi:10.1177/2472555217691450
Woerly, S., Fort, S., Pignot-Paintrand, I., Cottet, C., Carcenac, C., and Savasta, M. (2008). Development of a sialic acid-containing hydrogel of poly[N-(2-hydroxypropyl) methacrylamide]: characterization and implantation study. Biomacromolecules 9 (9), 2329–2337. doi:10.1021/bm800234r
Xie, C., Chen, Y., Wang, L., Liao, K., Xue, B., Han, Y., et al. (2024). Recent research of peptide-based hydrogel in nervous regeneration. Bioact. Mater 40, 503–523. doi:10.1016/j.bioactmat.2024.06.013
Xue, J., Liu, Y., Darabi, M. A., Tu, G., Huang, L., Ying, L., et al. (2019). An injectable conductive Gelatin-PANI hydrogel system serves as a promising carrier to deliver BMSCs for Parkinson's disease treatment. Mater. Sci. Eng. C 100, 584–597. doi:10.1016/j.msec.2019.03.024
Yao, B., Ye, Z., Lou, X., Yan, Q., Han, Z., Dong, Y., et al. (2022). Wireless rehabilitation training sensor arrays made with hot screen-imprinted conductive hydrogels with a low percolation threshold. ACS Appl. Mater. and Interfaces 14 (10), 12734–12747. doi:10.1021/acsami.2c01630
Zhou, B., Guo, J., Yang, C., and Kong, L. (2020). Upconversion-luminescent hydrogel optical probe for in situ dopamine monitoring. Photonics Res. 8 (11), 1800–1807. doi:10.1364/PRJ.403223
Zhou, L., Fan, L., Yi, X., Zhou, Z., Liu, C., Fu, R., et al. (2018). Soft conducting polymer hydrogels cross-linked and doped by tannic acid for spinal cord injury repair. ACS Nano 12 (11), 10957–10967. doi:10.1021/acsnano.8b04609
Keywords: hydrogels, neural tissue engineering, Parkinson’s disease, delivery systems, biosensing
Citation: Zhu P, Zhao Z and Gao Y (2025) Advances in hydrogel for diagnosis and treatment for Parkinson’s disease. Front. Pharmacol. 16:1552586. doi: 10.3389/fphar.2025.1552586
Received: 28 December 2024; Accepted: 28 January 2025;
Published: 12 February 2025.
Edited by:
Jianxun Ding, Chinese Academy of Sciences (CAS), ChinaReviewed by:
Yilong Cheng, Xi’an Jiaotong University, ChinaHuangfan Xie, Southwest Medical University, China
Yang Jianhai, Tianjin University, China
Copyright © 2025 Zhu, Zhao and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yufei Gao, Z2FveWZAamx1LmVkdS5jbg==